Revance Therapeutics Inc. (RVNC)

15.47
NASDAQ : Health Technology
Prev Close 15.96
Day Low/High 15.41 / 15.98
52 Wk Low/High 15.07 / 34.20
Avg Volume 472.50K
Exchange NASDAQ
Shares Outstanding 44.03M
Market Cap 702.70M
EPS -3.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Revance To Release Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 26, 2019

Revance To Release Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 26, 2019

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release fourth quarter and full year 2018...

Revance Therapeutics Becomes Oversold (RVNC)

Revance Therapeutics Becomes Oversold (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Revance Announces Closing Of Public Offering Of Common Stock

Revance Announces Closing Of Public Offering Of Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the closing of an underwritten public...

Revance Announces Pricing Of Public Offering Of Common Stock

Revance Announces Pricing Of Public Offering Of Common Stock

Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the pricing of an underwritten public...

Revance Announces Proposed Public Offering Of Common Stock

Revance Announces Proposed Public Offering Of Common Stock

Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a proposed underwritten public offering in...

Revance Announces Ground-Breaking Data Presentations At Leading International Neurotoxin Conference

Revance Announces Ground-Breaking Data Presentations At Leading International Neurotoxin Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced 11 clinical and non-clinical presentations for DaxibotulinumtoxinA for...

Revance Highlights Recent Regulatory Progress And Provides Anticipated 2019 Milestones

Revance Highlights Recent Regulatory Progress And Provides Anticipated 2019 Milestones

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced updates on meetings with the U.

First Week Of July 2019 Options Trading For Revance Therapeutics (RVNC)

First Week Of July 2019 Options Trading For Revance Therapeutics (RVNC)

Investors in Revance Therapeutics Inc saw new options become available this week, for the July 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 224 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Revance Announces China Market License Agreement With Fosun Pharma For RT002

Revance Announces China Market License Agreement With Fosun Pharma For RT002

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company has entered into a license agreement with Shanghai...

Revance's RT002 Demonstrates Unprecedented Efficacy And Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program

Revance's RT002 Demonstrates Unprecedented Efficacy And Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced its long-acting neuromodulator DaxibotulinumtoxinA for Injection (RT002)...

Revance To Participate In Upcoming Investor Conferences

Revance To Participate In Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

Revance To Participate In The Credit Suisse Healthcare Conference

Revance To Participate In The Credit Suisse Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Credit Suisse Healthcare...

Revance Releases Third Quarter 2018 Results

Revance Releases Third Quarter 2018 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the third quarter ended September 30, 2018.

Revance Therapeutics To Release Third Quarter 2018 Financial Results On Thursday, November 1, 2018

Revance Therapeutics To Release Third Quarter 2018 Financial Results On Thursday, November 1, 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release second quarter 2018 financial results on Thursday,...

Revance Therapeutics Appoints Tobin C. Schilke As Chief Financial Officer

Revance Therapeutics Appoints Tobin C. Schilke As Chief Financial Officer

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it has strengthened its leadership team with the appointment of Tobin C.

Revance To Participate In The Cantor Fitzgerald 2018 Global Healthcare Conference

Revance To Participate In The Cantor Fitzgerald 2018 Global Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Cantor Fitzgerald 2018 Global Healthcare...

Revance Receives Great Place To Work Certification

Revance Receives Great Place To Work Certification

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company was certified as a great workplace this month by the independent...

Notable Friday Option Activity: RVNC, MPWR, FIZZ

Notable Friday Option Activity: RVNC, MPWR, FIZZ

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Revance Therapeutics Inc , where a total of 1,134 contracts have traded so far, representing approximately 113,400 underlying shares. That amounts to about 61.8% of RVNC's average daily trading volume over the past month of 183,390 shares.

Revance Therapeutics Is Now Oversold (RVNC)

Revance Therapeutics Is Now Oversold (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

The entrance of more competition for Botox Cosmetic could expand the market, the drugmaker's top executive says at the Wells Fargo Healthcare Conference in Boston.

Revance Releases Second Quarter 2018 Results

Revance Releases Second Quarter 2018 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the second quarter ended June 30, 2018.

Revance Therapeutics To Release Second Quarter 2018 Financial Results On Thursday, August 2, 2018

Revance Therapeutics To Release Second Quarter 2018 Financial Results On Thursday, August 2, 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release second quarter 2018 financial results on Thursday, August...

Revance Doses First Patient In ASPEN Phase 3 Clinical Program Of RT002 Injectable For The Treatment Of Cervical Dystonia

Revance Doses First Patient In ASPEN Phase 3 Clinical Program Of RT002 Injectable For The Treatment Of Cervical Dystonia

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced initiation of patient dosing in the company's ASPEN Phase 3 clinical program for its...

Revance To Participate In The JMP Securities Life Sciences Conference 2018

Revance To Participate In The JMP Securities Life Sciences Conference 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the JMP Securities Life Sciences Conference 2018 in...

Revance To Participate In Upcoming Investor Conferences

Revance To Participate In Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

Revance Announces Departure Of Chief Financial Officer

Revance Announces Departure Of Chief Financial Officer

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that Lauren Silvernail has resigned as Revance's Chief Financial Officer and Chief...

Revance Announces Publication Of Positive 24-Week Duration Of Effect Results From Cervical Dystonia Phase 2 Trial In Movement Disorders Clinical Practice

Revance Announces Publication Of Positive 24-Week Duration Of Effect Results From Cervical Dystonia Phase 2 Trial In Movement Disorders Clinical Practice

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that results of a Phase 2 study of DaxibotulinumtoxinA for Injection (RT002) to treat...

TheStreet Quant Rating: D (Sell)